Anika Reports Top Line Data From CINGAL Study, Shares Slump
Zacks Investment Research | Jun 21, 2018 04:14AM ET
Shares of Anika Therapeutics Inc (NASDAQ:ANIK) slumped 37% after the company reported disappointing data from its phase III Cingal 16-02 study. The 16-02 trial compared Cingal, a combination of cross-linked HA and triamcinolone hexacetonide (TH), with TH alone and cross-linked HA in treating patients with osteoarthritis (OA) in the knee.
The primary endpoint was a comparison of the pain reduction of Cingal compared with TH alone at 26-weeks. While Cingal achieved greater pain reduction numerically at every time point in the study, the difference at 26-weeks did not reach statistical significance.
Year to date, share price of the company decreased 16.3% compared with the industry ’s decline of 5.7%.
The study showed a strong safety profile which matched with the previous clinical studies (13-01 phase III study). The duration of pain reduction was also similar to the previous study as patient improvement after Cingal injection was maintained near peak levels throughout the 26-week duration of the study.
Though the company expected Cingal to perform like it did in the other study, the difference in pain reduction seen in this study did not reach statistically significant levels at six months. Anika is currently following up with the patients in a prospectively designed extension phase of the trial, which will collect data through 39 weeks.
Cingal is the first and only commercially-available combination viscosupplement, and it is currently being used successfully by physicians to provide rapid and long-lasting relief from pain and discomfort caused by OA for patients in a growing number of countries.
The company will continue to monitor the results of the ongoing 3-month extension study and is actively reviewing the data and plans to work closely with regulators to come to an understanding of the next steps required to gain U.S. regulatory approval of Cingal.
Zacks Rank & Stocks to Consider
Anika has a Zacks Rank #3 (Hold).
Some better-ranked stocks from the same space are Illumina, Inc. (NASDAQ:ILMN) , Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) and ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) . While Illumina sports a Zacks Rank#1 (Strong Buy), Aeglea and ANI Pharmaceuticals carry a Zacks Rank #2 (Buy). You can see .
Get The News You Want
Illumina’s earnings per share estimates have moved up from $4.60 to $4.86 for 2018 and from $5.34 to $5.61 for 2019 over the past 60 days. The company delivered a positive earnings surprise in each of the trailing four quarters with an average beat of 23.17%. The stock has rallied 32.2% so far this year.
Aeglea’s loss per share estimates have narrowed from $1.93 to $1.67 for 2018 and from $3.86 to $3.57 for 2019 over the past 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 19.32%. The stock has rallied 101.3% so far this year.
ANI Pharmaceuticals’earnings per share estimates have moved up from $5.54 to $5.70 for 2018 and from $5.72 to $6.15 for 2019 over the past 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 8.69%. The stock has rallied 3.9% so far this year.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers.
Some are already reaching 265 miles on a single charge. With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research. It's not the one you think.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.